Special Issue

Multiple Myeloma: Diagnosis and Therapy

Message from the Guest Editors

Multiple myeloma (MM) is a heterogenous disease characterized by the presence of abnormal clonal plasma cells. Current first-line therapy for newly diagnosed MM patients; followed by autologous stem cell transplants with high-dose Melphalan in eligible patients; followed by maintenance until disease progression. In the past few years, minimal residual disease (MRD) has been used as an important prognostic tool for MM.

Many therapeutic regimens in combinations are available for patients with relapsed and refractory multiple myeloma, including higher generations of Imids and Pls. Chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell surface maturation antigen (BCMA) and bispecific antibodies have been approved for patients at different stages of relapse/progression from one to four prior lines of therapy. In addition, new derivatives of immunomodulatory drugs are in phase 2 and 3 studies in relapse/refractory MM.

This Special Issue will highlight the different approaches for the treatment of multiple myeloma that advance our understanding of targeting the different pathways in multiple myeloma.

Guest Editors

Dr. Yvonne A. Efebera

Division of Hematology, Blood and Marrow Transplant, OhioHealth, Columbus, OH 43214, USA

Dr. Nidhi Sharma

Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions

31 March 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/218689

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

